Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cardiac and Metabolic Effects of Dapagliflozin in the Failing Fontan Circulation: A Phase II, Prospective, Double-Blind Study

NCT06762964 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT06762964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06762964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cardiac and Metabolic Effects of Dapagliflozin in the Failing Fontan Circulation: A Phase II, Prospective, Double-Blind Study
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Recruiting
Start date
May 16, 2025
Completion date
February 28, 2027
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fontan circulation, hfpef - heart failure with preserved ejection fraction, single ventricle heart disease